Publication|Articles|February 2, 2024

Pharmaceutical Technology

  • Pharmaceutical Technology, February 2024
  • Volume 48
  • Issue 2
  • Pages: 10

Dissolution Testing Software

Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities.

The release of Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities. Among the key updates in Version 3.20 are an integrated media addition, a dosage weight correction feature, and run automation for complete systems.

The process of analyzing tests that employ changing or adding additional media during testing has been simplified and automated, and automatically pauses measurements for media changes, which generates a consolidated report with visual demarcation of media change instances.

Recording individual dosage weights are now allowed, enabling the correction of % dissolved/concentration values for each dosage form. Non-uniform dosage forms particularly benefit from this feature.

Complete run automation is now possible for Distek systems equipped with a dosage auto-dropper option. This culminates in the automatic generation, storage, and optional printing of final reports.

Distek


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.